Diarrhea Case Surveillance in the Enterics for Global Health Shigella Surveillance Study: Epidemiologic Methods

Atlas H.E.; Conteh B.; Islam M.T.; Jere K.C.; Omore R.; Sanogo D.; Schiaffino F.; Yousafzai M.T.; Ahmed N.; Awuor A.O.; Badji H.; Cornick J.; Feutz E.; Galagan S.R.; Haidara F.C.; Horne B.; Hossen M.I.; Hotwani A.; Houpt E.R.; Jallow A.F.; Karim M.; Keita A.M.; Keita Y.; Khanam F.; Liu J.; Malemia T.; Manneh A.; McGrath C.J.; Nasrin D.; Ndalama M.; Ochieng J.B.; Ogwel B.; Olortegui M.P.; Paredes L.F.Z.; Vasquez T.P.; Platts-Mills J.A.; Qudrat-E-Khuda S.; Qureshi S.; Rajib M.N.H.; Rogawski McQuade E.T.; Sultana S.; Tennant S.M.; Tickell K.D.; Witte D.; Yori P.P.; Cunliffe N.A.; Jahangir Hossain M.; Kosek M.N.; Kotloff K.L.; Qadri F.; Qamar F.N.; Tapia M.D.; Pavlinac P.B. · Open Forum Infectious Diseases (2024) · DOI: 10.1093/ofid/ofad664

Resumen

Background. Shigella is a leading cause of acute watery diarrhea, dysentery, and diarrhea-attributed linear growth faltering, a precursor to stunting and lifelong morbidity. Several promising Shigella vaccines are in development and field efficacy trials will require a consortium of potential vaccine trial sites with up-to-date Shigella diarrhea incidence data. Methods. The Enterics for Global Health (EFGH) Shigella surveillance study will employ facility-based enrollment of diarrhea cases aged 6–35 months with 3 months of follow-up to establish incidence rates and document clinical, anthropometric, and financial consequences of Shigella diarrhea at 7 country sites (Mali, Kenya, The Gambia, Malawi, Bangladesh, Pakistan, and Peru). Over a 24-month period between 2022 and 2024, the EFGH study aims to enroll 9800 children (1400 per country site) between 6 and 35 months of age who present to local health facilities with diarrhea. Shigella species (spp.) will be identified and serotyped from rectal swabs by conventional microbiologic methods and quantitative polymerase chain reaction. Shigella spp. isolates will undergo serotyping and antimicrobial susceptibility testing. Incorporating population and healthcare utilization estimates from contemporaneous household sampling in the catchment areas of enrollment facilities, we will estimate Shigella diarrhea incidence rates. Conclusions. This multicountry surveillance network will provide key incidence data needed to design Shigella vaccine trials and strengthen readiness for potential trial implementation. Data collected in EFGH will inform policy makers about the relative importance of this vaccine-preventable disease, accelerating the time to vaccine availability and uptake among children in high-burden settings. © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Instituciones: Universidad Peruana Cayetano Heredia